Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for ARSENIC TRIOXIDE
- Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
- Efficacy, Tolerability and Safety of Intravenous D-VC With ATO in Patients With Advanced/Metastatic Colorectal Cancer
- South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol
- Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL.
- Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid
- A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
- Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation
- Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
- An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
- Arsenic Trioxide for Structural p53 Mutations
- Oral Arsenic Trioxide for NPM1-mutated AML
- Frontline Oral Arsenic Trioxide for APL
- Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer
- Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation
- Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL
- The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART
- Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS
- Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia
- Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma
- Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
- Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)
- Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders
- Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia
- Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide
- Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
- Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
- Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)
- Combination of Ibrutinib and As2O3 in the Treatment of CLL
- Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer
- Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
- Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
- A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
- Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
- Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
- Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI
- Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC
- Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
- Proteasome Inhibition in Acute Promyelocytic Leukemia
- Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma
- Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
- Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)
- Study of Arsenic Trioxide in Small Cell Lung Cancer
- Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
- Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
- Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)
- Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
- Trisenox® in Women With Metastatic Endometrial Cancer
- Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
- Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
- Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
- Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide
- Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes
- Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma
- Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia
- Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia
- New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
- Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
- Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome
- Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
- A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
- Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis
- Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy
- S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
- Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
- Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia
- Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia
- Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
- Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma
- S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
- Phase III Trial in Acute Promyelocytic Leukemia Patients
- Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
- Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
- Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment
- All-trans Retinoic Acid, and Arsenic +/- Idarubicin
- Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
- Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
- Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
- Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
- Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
- A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome
- A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
- Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
- Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)
- Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma
- Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
- Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML
- Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma
- Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma
- Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia
- Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery
- Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma
- Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
- Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
- Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes
- Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas
- Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
- Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes
- Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer
- Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
- Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
- Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine
- Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
- Arsenic Trioxide in Treating Men With Germ Cell Cancer
- Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
- Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
- Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma
- Arsenic Trioxide in Treating Patients With Multiple Myeloma
- Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
- Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
- Arsenic Trioxide in Treating Patients With Urothelial Cancer
- Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
- Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
- Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia
- Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
- Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia
- Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma
- Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer
- Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia
- Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia
- Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
- Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease
- Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer
- Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma
- Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy
- Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
- Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
- Arsenic Trioxide in Treating Patients With Advanced Solid Tumors
- Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
Clinical trials list
click for details